OncLive® On Air S13 Ep35: Telisotuzumab Vedotin Represents a New Treatment Development for c-Met–Overexpressing NSCLC: With Joshua K. Sabari, MD
Jul 24, 2025
In this discussion, Dr. Joshua K. Sabari, an expert in lung cancer at NYU Grossman School of Medicine, dives into the promising new treatment, telisotuzumab vedotin, for c-Met overexpressing NSCLC. He highlights significant results from the phase 2 LUMINOSITY study and discusses how this therapy could shift the treatment landscape. Dr. Sabari also addresses ongoing trials that may redefine patient management, emphasizing the importance of balancing efficacy with the careful monitoring of potential toxicities.
AI Snips
Chapters
Transcript
Episode notes
ADC Mechanism Targets MET
- Telisotuzumab vedotin is an antibody–drug conjugate that uses an anti‑MET antibody linked to an MMAE cytotoxic payload.
- It binds MET on tumor cells to deliver the warhead directly and increase tumor cell kill.
FDA And NCCN Guidance On MET Expression
- The FDA approved telisotuzumab vedotin for MET 3+ tumors after frontline chemotherapy and immunotherapy.
LUMINOSITY Showed Strong Response Rates
- The phase II LUMINOSITY trial reported 35% ORR in MET 3+ and 24% in MET 2+ patients.